← Oncology Approval Tracker

FDA DECISION ·

Revuforj

revumenib · Syndax Pharmaceuticals

FDA approvalNew therapyAcute leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults and children aged 1 year and older with relapsed or refractory acute leukemia bearing a KMT2A translocation.

LAMPGEN ANALYSIS

Why it matters

The menin inhibitor provides a targeted option across acute leukemia lineages that share this translocation.

What research teams should watch

Confirm the translocation rather than a nonspecific KMT2A result, and build a rapid escalation plan for differentiation syndrome.

PRIMARY RECORDS

Sources